Use of stochastic stimulation model to identify an efficient protocol for ovarian cancer screening

Controlled Clinical Trials

Volumn 18, Issue 3, 1997, Pages 251-270

  Urban, Nicole ^a,b,c   Drescher, Charles ^c,d   Etzioni, Ruth ^a   Colby, Chris ^a,e  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Marsha Rivkin Ctr Ovarian Cancer R   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e DIVISION OF RESEARCH   (United States)

Author keywords

Cost effectiveness; Ovarian cancer; Screening; Stimulation model; Trial design

Indexed keywords

CA 125 ANTIGEN; TUMOR ANTIGEN;

AGE; ARTICLE; CANCER SCREENING; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPUTER SIMULATION; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; FEMALE; HUMAN; MASS SCREENING; MORTALITY; OVARY CANCER; PREDICTION; STOCHASTIC MODEL; THEORETICAL STUDY; TRANSVAGINAL ECHOGRAPHY; AGED; BLOOD; COHORT ANALYSIS; COST BENEFIT ANALYSIS; ECONOMICS; ENDOSCOPIC ECHOGRAPHY; MIDDLE AGED; OVARY TUMOR; PREDICTION AND FORECASTING; STATISTICAL MODEL; STATISTICS; SURVIVAL;

AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; COHORT STUDIES; COST-BENEFIT ANALYSIS; ENDOSONOGRAPHY; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; MODELS, STATISTICAL; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; STOCHASTIC PROCESSES; SURVIVAL ANALYSIS;

EID: 0030612188     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-2456(96)00233-4     Document Type: Article

References (49)

1. Jacobs IJ, Oram DA. Potential screening tests for ovarian cancer. In: Sharp F, Mason WP, Leake RE, eds. Ovarian Cancer. New York: WW Norton, 1990.
2. van Nagell JR, Higgins RV, Donaldson ES, et al. Transvaginal sonography as a screening method for ovarian cancer: a report of the first 1000 cases screened. Cancer 1990;65:573-577.
3. Skates SJ, Singer DE. Quantifying the potential benefit of CA 125 screening for ovarian cancer. J Clin Epidemiol 1991;44:365-380.
4. Jacobs I, Stabile I, Bridges J, et al. Multimodal approach to screening for ovarian cancer. Lancet 1988;i:268-271.
5. Kramer BS, Gohagan J, Prorok PC, Smart C. A National Cancer Institute-sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers. Cancer 1993;71: 589-593.
6. Ovarian Cancer: Screening, Treatment, and Follow-up. NIH Consensus Statement. 5-7 Apr 1994; 12[3]:1-30.
7. Miller BA, Ries LAG, Hankey BF, et al, eds. SEER Cancer Statistics Review. 1973-1991. National Cancer Institute, NIH Publication No. 94-2789, 1994.
8. Manual for Staging of Cancer. 2nd ed. American Joint Committee on Cancer, 1983.
9. Campbell S, Bhan V, Royston P, Whitehead MI, Collins WP. Transabdominal ultrasound screening for early ovarian cancer. Br Med J 1989;299:1363-1367.
10. Bourne T, Campbell S, Steer C, Whitehead MI, Collins WP. Transvaginal color flow imaging; a possible new screening technique for ovarian cancer. B Med J 1989;299:1367-1370.
11. Jacobs I. Screening for early ovarian cancer [letter to the editor]. Lancet 1988;ii:171.
12. Keatinge R. Transabdominal ultrasound screening for early ovarian cancer [letter to the editor]. Br Med J 1990;300: 193-194.
13. Dawson A. Transabdominal ultrasound screening for early ovarian cancer [letter to the editor]. Br Med J 1990;300:193-194.
14. van Nagell JR, Depriest P, Puls L, et al. Ovarian cancer screening in asymptomatic postmenopausal women by transvaginal sonography. Cancer 1991,68[3]:458-462.
15. Jacobs I, Davies AP, Bridges J, et al. Prevalence screening for ovarian cancer in post-menopausal women by CA 125 measurement and ultrasonography. Br Med J 1993;306:1030-1034.
16. Bast RC, Siegal FP, Runowicz C, et al. Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinoma. Gynecol Oncol 1985;22:115-120.
17. Zwirner M, Bieglmayer CH, Klapdor R, Kreienberg R, Luthgens M. An international proficiency study with the tumor marker CA 125. Int J Biol Markers 1990;5:55-60.
18. Zurawski VR, Sjovall K, Schoenfeld DA, et al. Prospective evaluation of serum CA 125 levels in a normal population, phase I: the specificities of single and serial determinations in testing for ovarian cancer. Gynecol Oncol 1990;36:299-305.
19. Zurawski VR, Orjaseter H, Andersen A, Jellum E. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int J Cancer 1988;42:677-680.
20. Einhorn N, Sjovall K, Schoenfeld DA, et al. Early detection of ovarian cancer using the CA 125 radioimmunoassay [RIA]. Proc Am Soc Clin Oncol 1990;9:157.
21. Maggino T, Sopracordevole F, Matarese M, Di Pasquale C, Tambuscio G. CA-125 serum level in the diagnosis of pelvic masses: comparison with other methods. Eur J Gynaecol Oncol 1987;6:590-595.
22. Zurawski VR, Broderick S, Pickens P, Knapp RC, Bast RC. Serum CA 125 levels in a group of nonhospitalized women: relevance for the early detection of ovarian cancer. Obstet Gynecol 1987;69:606-611.
23. Bast RC, Knauf S, Epenetos A, et al. Coordinate elevation of serum markers in ovarian cancer but not in benign disease. Cancer 1991;68:1758-1763.
24. Westoff C, Gollub E, Patel J, Rivera H, Bast R. CA 125 levels in menopausal women. Obstet Gynecol 1990;76:428-431.
25. Jacobs I, Bast RC Jr. The CA 125 tumor associated antigen: a review of the literature. Human Reprod 1989;4:1-12.
26. Baker SG, Heidenberger K. Choosing sample sizes to maximize expected health benefits subject to a constraint on total trial costs. Med Decis Making 1989;9:14-25.
27. Detsky AS. Using cost-effectiveness analysis to improve the efficiency of allocating funds to clinical trials. Stat Med 1990;9:173-184.
28. Shwartz M. A mathematical model used to analyze breast cancer screening strategies. Operations Research 1978;26:937-955.
29. Shwartz M. Validation of a model of breast cancer screening: an outliner observation suggests the value of breast self-examinations. Med Decis Making 1992;12[3] :222-228.
30. Habbema JDF, Oortmarssen GJ, Lubbe JN, van der Maas PJ. The MISCAN simulation program for the evaluation of screening for disease. Biometrika 1984;20:79-93.
31. Urban N, Baker M. The Women's Health Trial as an investment. Med Decis Making 1989;9:59-64.
32. Detsky AS. Using economic analysis to determine the resource consequences of choices made in planning clinical trials. J Chron Dis 1985;38:753-765.
33. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practice. N Engl J Med 1977;296:716-721.
34. Doubilet P, Weinstein MC, McNeil BJ. Use and misuse of the term "cost-effective" in medicine. N Engl J Med 1986;314:253-256.
35. Russell LB. Is Prevention Better Than Cure? Washington, DC: The Brookings Institution, 1986.
36. Gauss 386 2.1, Aptech Systems Inc, Kent, WA, 1984-1991.
37. U.S. Department of Health and Human Services. PHS Centers for Disease Control. NCHS 1991. Vital Statistics of the U.S. 1988 Vol. II Mortality, Part A, Table 1-4. Sect. 1, General Mortality, 7.
38. Woolas RP, Fengiji X, Jacobs IJ, et al. Elevation of multiple serum markers in patients with stage I ovarian cancer. J Nat Cancer Inst 1993;85:1748-1751.
39. Campbell S, Royston P, Bhan V, Whitehead MI, Collins WP. Novel screening strategies for early ovarian cancer by transabdominal ultrasonography. Br J Obstet & Gynaecol 1990;97:304-311.
40. Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer-related health services research using linked Medicare-tumor registry database. Med Care. 1993;31:732-748.
41. Etzioni R, Urban N. Estimating the costs attributable to a disease with application to ovarian cancer. J Clin Epi 1996;49:95-103.
42. Keeler EB, Cretin S. Discounting of life-saving and other non-monetary effects. Management Sci 1983;29:300-306.
43. Karlan BY, Raffel LJ, Crvenkovic G. A multidisciplinary approach to the early detection of ovarian carcinoma: rationale, protocol, design, and early results. Am J Obs & Gyn 1993;169:494-501.
44. Snedecor GW, Cochran WG. Statistical Methods Ames, Iowa: Iowa State Univ. Press, 1971.
45. Smith LH, Oi RH. Detection of malignant ovarian neoplasms: a review of the literature. II. laboratory detection. Obst & Gynecol Survey 1984;39:329-360.
46. Bast RC Jr, Klug TL, St. John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883-887.
47. Shwartz M. Estimates of lead time and length bias in a breast cancer screening program. Cancer 1980;46:844-854.
48. Zurawski VR, Knapp RC, Einhorn N, et al. An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma. Gynecol Oncol 1988;30:7-14.
49. Bast RC. Perspectives in the future of cancer markers. Clin Chem 1993;39:2444-2451.